Published in Endocrinology on March 26, 2013
Effect of physical training on liver expression of activin A and follistatin in a nonalcoholic fatty liver disease model in rats. Braz J Med Biol Res (2014) 0.82
A soluble activin receptor type IIB does not improve blood glucose in streptozotocin-treated mice. Int J Biol Sci (2015) 0.79
A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol (2006) 10.67
Human fatty liver disease: old questions and new insights. Science (2011) 8.03
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem (2004) 7.91
Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell (2000) 5.92
Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem (2002) 5.89
Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A (2010) 4.40
"New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab (2005) 3.86
SREBP transcription factors: master regulators of lipid homeostasis. Biochimie (2004) 3.85
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem (2009) 3.41
Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest (2006) 3.21
Multiple defects and perinatal death in mice deficient in follistatin. Nature (1995) 2.96
Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways. J Biol Chem (1995) 2.58
Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology (2010) 2.47
A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A (2010) 2.34
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
Proteins under new management: lipid droplets deliver. Trends Cell Biol (2007) 2.12
CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J Lipid Res (2010) 1.79
Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol (1985) (2010) 1.76
Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res (2010) 1.75
Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology (2006) 1.71
The biology of activin: recent advances in structure, regulation and function. J Endocrinol (2009) 1.64
FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci U S A (2007) 1.55
Isolation and culture of adult mouse hepatocytes. Methods Mol Biol (2010) 1.43
The metabolically benign and malignant fatty liver. Diabetes (2011) 1.39
Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver. J Biol Chem (2000) 1.37
Activin a plays a critical role in proliferation and differentiation of human adipose progenitors. Diabetes (2010) 1.31
Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res (2008) 1.28
Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology (2008) 1.27
Human follistatin-related protein: a structural homologue of follistatin with nuclear localization. Endocrinology (2001) 1.21
Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol Cell Biol (2012) 1.14
Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease. J Hepatol (2008) 1.03
A role for activin A and betacellulin in human fetal pancreatic cell differentiation and growth. J Clin Endocrinol Metab (2000) 1.03
A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology (2010) 1.01
Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males. J Clin Endocrinol Metab (2011) 1.01
Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology (2010) 0.96
Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology (2002) 0.95
Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis. Obesity (Silver Spring) (2011) 0.93
A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol (2009) 0.92
The follistatin-288 isoform alone is sufficient for survival but not for normal fertility in mice. Endocrinology (2009) 0.90
Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation. Diabetes (2011) 0.86
Activin B inhibits lipolysis in 3T3-L1 adipocytes. Biochem Biophys Res Commun (2010) 0.86
Soluble activin receptor type IIB treatment does not cause fat loss in mice with diet-induced obesity. Diabetes Obes Metab (2011) 0.84
Lipoprotein lipase-facilitated uptake of LDL is mediated by the LDL receptor. J Lipid Res (2006) 0.83
Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet (2006) 8.32
Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem (2005) 2.07
DRAGON, a bone morphogenetic protein co-receptor. J Biol Chem (2005) 1.89
The biology of activin: recent advances in structure, regulation and function. J Endocrinol (2009) 1.64
FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci U S A (2007) 1.55
Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem (2007) 1.45
Emerging roles for the TGFbeta family in pancreatic beta-cell homeostasis. Trends Endocrinol Metab (2010) 1.05
The role of follistatin domains in follistatin biological action. Mol Endocrinol (2003) 1.01
Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis. J Clin Endocrinol Metab (2005) 0.99
Dragon enhances BMP signaling and increases transepithelial resistance in kidney epithelial cells. J Am Soc Nephrol (2010) 0.98
Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology (2002) 0.95
Leptin and soluble leptin receptor in follicular fluid. J Assist Reprod Genet (2003) 0.89
Revascularization and remodelling of pancreatic islets grafted under the kidney capsule. J Anat (2007) 0.89
Heparin and activin-binding determinants in follistatin and FSTL3. Endocrinology (2004) 0.88
Differential synthesis and action of TGFß superfamily ligands in mouse and rat islets. Islets (2011) 0.87
Follistatin regulates germ cell nest breakdown and primordial follicle formation. Endocrinology (2010) 0.85
Ovarian brain-derived neurotrophic factor is present in follicular fluid from normally cycling women. Fertil Steril (2003) 0.85
In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2. J Biol Chem (2004) 0.83
Regulation of endometrial adenocarcinoma cell proliferation by Activin-A and its modulation by 17beta-estradiol. Mol Cell Endocrinol (2002) 0.82
The role of activin in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia (2011) 0.78
Follistatin-like 3 (FSTL3) mediated silencing of transforming growth factor β (TGFβ) signaling is essential for testicular aging and regulating testis size. Endocrinology (2013) 0.78
Heparin-induced thrombocytopenia following pancreatectomy and islet auto-transplantation. Clin Transplant (2006) 0.77
Activin subunit and receptor expression in normal and cleft human fetal palate tissues. Pediatr Dev Pathol (2007) 0.77
Development of a bioartificial new intestinal segment using an acellular matrix scaffold. Gut (2007) 0.76